Join Now

Author Archives: admin

Clene announces results of exploratory analysis in treatment of ALS

SALT LAKE CITY, March 09, 2023 (GLOBE NEWSWIRE) — Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, today announced new results from exploratory analyses including delayed time to key clinical progression events in people […]

Posted in BioUtah News | Comments Off on Clene announces results of exploratory analysis in treatment of ALS

Spectrum Solutions Acquires Alimetrix, Inc. and Microarrays, Inc. to Expand Laboratory Products and Testing Capabilities

SALT LAKE CITY–(BUSINESS WIRE)–Spectrum Solutions® today announced the acquisitions of Alimetrix, Inc., a CLIA and CAP accredited molecular diagnostic laboratory skilled at custom qualitative and quantitative assay development, and Microarrays, Inc., a leader in customer array-based products that are used as biological research tools – gene expression arrays, reverse and forward phase protein arrays. These […]

Posted in BioUtah News | Comments Off on Spectrum Solutions Acquires Alimetrix, Inc. and Microarrays, Inc. to Expand Laboratory Products and Testing Capabilities

Nomi Health Launches Charitable Foundation to Expand Access to Affordable, High-Quality Healthcare

The Nomi Health Charitable Foundation will broaden the company’s philanthropic investments in healthcare equity, financial and health literacy, STEAM education and social determinants of health. “Frontline Futures Initiative” will offer tuition assistance and support to underserved individuals pursuing careers in healthcare. OREM, Utah–(BUSINESS WIRE)–Nomi Health, a direct healthcare company, has announced the creation of the […]

Posted in BioUtah News | Comments Off on Nomi Health Launches Charitable Foundation to Expand Access to Affordable, High-Quality Healthcare

University of Utah, TikkunLev to accelerate heart-failure gene therapy

Salt Lake City – The University of Utah, one of the nation’s leading research universities, and TikkunLev Therapeutics, a gene therapy company, have announced a new partnership to accelerate an innovative heart failure gene therapy. The agreement is an exclusive world-wide license and includes a sponsored research program to support future FDA filings. The discovery […]

Posted in BioUtah News | Comments Off on University of Utah, TikkunLev to accelerate heart-failure gene therapy

Carterra expands best-in-class franchise with the launch of the LSAXT high-throughput SPR biosensor at SLAS 2023

New instrument provides greater sensitivity to enable additional applications for discovery and characterization of novel therapeutics with unrivaled throughput and efficiency Salt Lake City, Utah —February 27, 2023—Carterra Inc., the world leader in innovative technologies enabling high-throughput biology, launched its latest HT-SPR instrument, the LSAXT, at the Society for Laboratory Automation and Screening (SLAS) Conference and […]

Posted in BioUtah News | Comments Off on Carterra expands best-in-class franchise with the launch of the LSAXT high-throughput SPR biosensor at SLAS 2023

Illumina and Myriad Genetics expand partnership to broaden access to HRD testing in the United States

Strategic partnership offers a unique combination of diagnostic development and commercialization capabilities to the pharmaceutical industry SALT LAKE CITY, March 02, 2023 (GLOBE NEWSWIRE) — Myriad Genetic, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the […]

Posted in BioUtah News | Comments Off on Illumina and Myriad Genetics expand partnership to broaden access to HRD testing in the United States

BioUtah Recognizes Rare Disease Day 2023

BioUtah President and CEO, Kelvyn Cullimore, commented on Rare Disease Day held on February 28, 2023. “Today is Rare Disease Day 2023, a day being recognized in countries around the world. Here in Utah, Gov. Spencer J. Cox has declared February 28, 2023 Rare Disease Day in the state. We are marking this occasion with […]

Posted in BioUtah News | Leave a comment

SDNA Saliva Collection FDA 510(k) Class II Medical Device Clearance

SALT LAKE CITY, UTAH—Spectrum Solutions, LLC today announced the U.S. Food and Drug Administration (FDA) has granted 510(k) Class II clearance to the SDNA Saliva Collection Device as a microbial nucleic acid storage and stabilization device. The SDNA device is driving a new era of healthcare that turns to salivary collection and preservation as a […]

Posted in BioUtah News | Leave a comment

Merit Medical Receives FDA Breakthrough Device Designation for the New SCOUT® MD™ Surgical Guidance System

Next-generation system helps improve surgical precision to enhance patient care in breast and other soft tissue cancer treatment SOUTH JORDAN, Utah, Feb. 16, 2023 (GLOBE NEWSWIRE) — Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today the FDA has granted Breakthrough Device Designation for the SCOUT MD […]

Posted in BioUtah News | Leave a comment

HHS Releases New Payment Models for Prescription Drugs

HHS released on Tuesday, three new payment models that will be tested through the Centers for Medicare & Medicaid Services Innovation Center (CMS Innovation Center) to see whether they lower high drug costs under Medicare and Medicaid. The models are outlined as part of a larger HHS report conducted in response to an executive order […]

Posted in Policy News | Leave a comment

BioUtah on Capitol Hill

The Utah State Legislature has hit its halfway point in the 2023 session. Since day one, BioUtah President and CEO, Kelvyn Cullimore, and industry lobbyist, Chris Bleak, have been on the Hill engaging with lawmakers on a number of issues that impact our industry. Yesterday, Cullimore testified before the House Health and Human Services Committee […]

Posted in BioUtah News | Leave a comment

Sumitomo Pharma Oncology Presented Preliminary Data From Phase 1/2 Clinical Study Evaluating Investigational Agent TP-3654 in Patients With Myelofibrosis at American Society of Hematology 2022 Annual Meeting & Exposition

Sumitomo Pharma Oncology presented new data from the ongoing Phase 1/2 study evaluating TP-3654.

Posted in BioUtah News | Tagged | Leave a comment